Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).

The Journal of dermatological treatment·2025

Same author

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.

ESMO open·2023

Same author

Successful use of dupilumab for the treatment of atopic dermatitis on the genitals, a neglected anatomical site.

Clinical and experimental dermatology·2021

Same author

Post-recombination effects in confined gases photoionized at megahertz repetition rates.

Optics express·2021

Same author

Fast recognition of Loxosceles rufescens in Italian spider bites to avoid misdiagnosis, alarmism and start a prompt treatment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

Efficient single-cycle pulse compression of an ytterbium fiber laser at 10 MHz repetition rate.

Optics express·2020

Same journal

Identification of RRM2 as a key regulator of malignant epithelial cells in gastric cancer through single‑cell transcriptomics.

Oncology reports·2026

Same journal

Impact of WFDC2 on the biological functions of cervical cancer cells and the regulation of the ERK/NF‑κB signaling pathway.

Oncology reports·2026

Same journal

Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.

Oncology reports·2026

Same journal

Research advances on DKK1 in head and neck squamous cell carcinoma: Linking molecular mechanisms to clinical applications (Review).

Oncology reports·2026

Same journal

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.

Oncology reports·2026

Same journal

A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer.

Oncology reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Interleukin-2 and interferon alpha 2 combination.

P Pronzato¹, A Vigani, F Vaira

¹OSPED S ANDREA,DEPT UROL,I-19100 LA SPEZIA,ITALY. OSPED S ANDREA,DEPT RADIOTHERAPY,I-19100 LA SPEZIA,ITALY.

Oncology Reports

|May 20, 2011

Summary

This summary is machine-generated.

This study found that subcutaneous recombinant interleukin-2 and interferon alpha 2b showed acceptable toxicity but no objective response in advanced renal cell carcinoma patients. Median survival was 16 months in this pretreated group.

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: Jun 1, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

Oncology
Immunotherapy

Background:

Advanced renal cell carcinoma (RCC) has limited treatment options.
Interferon therapy is a known treatment for RCC.
Recombinant interleukin-2 (IL-2) is being explored for its anti-cancer effects.

Purpose of the Study:

To evaluate the activity and toxicity of subcutaneous recombinant IL-2 combined with interferon alpha 2b.
To assess the outcomes in patients with advanced RCC who had poor prognostic factors and prior interferon treatment.

Main Methods:

A series of 14 patients with advanced RCC were treated with subcutaneous recombinant IL-2 and interferon alpha 2b.
Patients had pre-existing poor prognostic factors and had received prior interferon therapy.

Main Results:

No objective tumor response was observed in any of the patients.
The median survival time for the group was 16 months, with a range of 3 to 19 months.
The toxicity associated with the treatment regimen was deemed acceptable.

Conclusions:

Subcutaneous recombinant IL-2 and interferon alpha 2b combination therapy did not yield objective responses in pretreated advanced RCC patients.
The treatment demonstrated acceptable toxicity despite poor prognostic factors.
Further research may be needed to identify effective immunotherapy combinations for advanced RCC.